Is allogeneic transplant for solid tumors still alive?

Immune therapy for cancer is being pursued with extraordinary interest by investigators and pharma industries, given the new scientific acquisitions on immune mechanisms that control cancer.The paradigm for immune therapy of cancer is allogeneic stem cell transplantation, whose therapeutic effect is carried out by immunocompetent T cells of the donor, an effect known as graftversus- leukemia or graft-versus-tumor effect (GVT).Thirty eight Centers who had transplanted 63 patients were contacted. Eighteen (47%) agreed to contribute data, for a total of 32 patients (51%).In conclusion, allograft for solid tumors as adoptive immunotherapy is still being used in EBMT Centers, in a few centers and in a few selected indications. Centers are willing to share data, adopt common protocols and continue to use this strategy in highly selected cases.